Search for
Drug of Abuse-Opiates By Rapid
Blood
Report in 4Hrs
At Home
No Fasting Required
Details
Rapid urine/blood screening panels.
₹222₹317
30% OFF
Drug of Abuse-Opiates By Rapid
- Why is it done?
- Detects the presence of opiate drugs (morphine, codeine, and their metabolites) in urine samples using rapid immunoassay technology
- Screen for illicit drug use in workplace, legal, or clinical settings
- Monitor patients on opioid pain management or addiction treatment programs
- Evaluate suspected opioid overdose or toxicity in emergency settings
- Assess medication compliance in patients receiving prescribed opioids
- Perform rapid point-of-care testing with results typically available within minutes
- Normal Range
- Negative Result: Less than the cutoff threshold (typically <300 ng/mL)
- Positive Result: Greater than or equal to the cutoff threshold (≥300 ng/mL), indicating presence of opiates
- Units of Measurement: nanograms per milliliter (ng/mL)
- Invalid Result: No line appears on the test strip, indicating procedural error or inadequate sample
- Negative results typically indicate absence of opioid use, while positive results require confirmation with more specific testing such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS)
- Interpretation
- Negative Result Interpretation: No detectable opiates present in the sample at or above the cutoff level, suggesting abstinence or insufficient opiate concentration
- Positive Result Interpretation: Opiates detected above the threshold, suggesting recent use of heroin, morphine, or codeine-containing products
- False Positives: May occur from consumption of poppy seed foods, certain medications (codeine in cough syrups or pain relievers), or cross-reactivity with similar compounds
- False Negatives: Possible if opiates are below the detection threshold or when semi-synthetic opioids (e.g., heroin metabolite 6-acetylmorphine) are present but not detected by this rapid screening
- Factors Affecting Results: • Hydration status and urine concentration • Time elapsed since drug consumption • Medication history and recent drug intake • Individual metabolism rates • Sample degradation or improper storage • Specimen contamination or dilution • Patient age and kidney function
- Clinical Significance: Rapid screening test useful for initial assessment but should not be considered definitive; confirmatory testing is required for medical-legal purposes or treatment decisions
- Associated Organs
- Primary Organ Systems: Central Nervous System (CNS), Gastrointestinal System, Respiratory System
- Conditions Associated with Positive Results: • Opioid use disorder and substance abuse • Heroin addiction • Illicit drug use • Medication non-compliance in pain management • Acute opioid overdose • Polysubstance abuse with opioids
- Diseases/Conditions Diagnosed or Monitored: • Opioid addiction and dependence • Substance use disorder • Medication-assisted treatment (MAT) compliance • Pain management compliance • Acute intoxication
- Potential Complications of Opioid Abuse: • Respiratory depression and hypoxia • Cardiovascular complications (arrhythmias, myocarditis) • Liver damage and hepatitis from contaminated drugs • Pulmonary edema • CNS depression and altered mental status • Infectious complications (HIV, hepatitis C from injection) • Gastrointestinal dysfunction and constipation • Renal impairment • Overdose and death
- Follow-up Tests
- Confirmatory Testing (if positive): Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Mass Spectrometry (LC-MS) for definitive identification
- Expanded Drug Panel: Testing for other drugs of abuse including amphetamines, cocaine, benzodiazepines, cannabis, and methamphetamine
- Liver Function Tests: AST, ALT, bilirubin to assess hepatic status in chronic users
- Infectious Disease Screening: HIV antibody test, hepatitis B and C serology for intravenous drug users
- Renal Function Tests: Serum creatinine and BUN to assess kidney function
- Cardiac Evaluation: ECG and troponin levels if overdose or cardiac complications suspected
- Respiratory Assessment: Arterial blood gas (ABG) and chest imaging if respiratory depression suspected
- Therapeutic Drug Monitoring: Methadone or buprenorphine levels if enrolled in medication-assisted treatment
- Monitoring Frequency: Regular testing recommended weekly to monthly depending on treatment program requirements, legal obligations, or clinical circumstances
- Fasting Required?
- Fasting: No fasting required
- Sample Type: Urine specimen (midstream clean-catch or random collection)
- Patient Preparation Instructions: • Provide urine sample in clean collection cup (typically 30-50 mL minimum) • Ensure proper specimen labeling with patient identification • Collect sample using clean-catch midstream technique when possible to minimize contamination • Handle specimen according to chain-of-custody procedures for legal cases • Do not dilute or tamper with specimen
- Medications to Avoid: No specific medications must be discontinued; however, inform healthcare provider of all current medications as some cough syrups, pain relievers, and prescription opioids may cause positive results
- Special Considerations: • Poppy seed foods should be avoided 24-48 hours before testing if possible (can cause false positives) • Excessive fluid intake before collection may dilute specimen and affect results • Temperature regulation may be important as some rapid tests check for specimen validity (temperature stripping) • Specimen should be used promptly or stored according to laboratory guidelines • Directly observed collection may be required for legal/workplace testing • Inform patient that results will be reported to relevant parties per established protocols
How our test process works!
